➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
AstraZeneca
Dow
McKesson
Baxter

Last Updated: October 25, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR PURINETHOL

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for PURINETHOL

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002618 ↗ Combination Chemotherapy in Treating Pediatric Patients With Advanced-Stage Large Cell Lymphoma Completed National Cancer Institute (NCI) Phase 3 1994-12-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Giving the drugs in different doses may kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy with various combinations of drugs in treating pediatric patients with advanced-stage large cell lymphoma.
NCT00002618 ↗ Combination Chemotherapy in Treating Pediatric Patients With Advanced-Stage Large Cell Lymphoma Completed Children's Oncology Group Phase 3 1994-12-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Giving the drugs in different doses may kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy with various combinations of drugs in treating pediatric patients with advanced-stage large cell lymphoma.
NCT00002744 ↗ Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia Completed National Cancer Institute (NCI) Phase 3 1996-05-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways may kill more cancer cells. It is not yet known which regimen of combination chemotherapy is more effective for acute lymphoblastic leukemia PURPOSE: Randomized phase III trial to compare different regimens of combination chemotherapy in treating children who have newly diagnosed acute lymphoblastic leukemia.
NCT00002744 ↗ Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia Completed Children's Oncology Group Phase 3 1996-05-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways may kill more cancer cells. It is not yet known which regimen of combination chemotherapy is more effective for acute lymphoblastic leukemia PURPOSE: Randomized phase III trial to compare different regimens of combination chemotherapy in treating children who have newly diagnosed acute lymphoblastic leukemia.
NCT00002812 ↗ Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia Completed National Cancer Institute (NCI) Phase 3 1996-09-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug and giving the drugs in different combinations may kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of standard combination chemotherapy treatment with more intensive combination chemotherapy in treating children with acute lymphocytic leukemia.
NCT00002812 ↗ Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia Completed Children's Oncology Group Phase 3 1996-09-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug and giving the drugs in different combinations may kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of standard combination chemotherapy treatment with more intensive combination chemotherapy in treating children with acute lymphocytic leukemia.
NCT00003671 ↗ Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphocytic Leukemia Completed National Cancer Institute (NCI) Phase 2 1998-12-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating children who have newly diagnosed acute lymphocytic leukemia.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for PURINETHOL

Condition Name

Condition Name for PURINETHOL
Intervention Trials
Leukemia 7
Acute Lymphoblastic Leukemia 6
Crohn's Disease 3
Recurrent B Acute Lymphoblastic Leukemia 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for PURINETHOL
Intervention Trials
Precursor Cell Lymphoblastic Leukemia-Lymphoma 20
Leukemia, Lymphoid 19
Leukemia 18
Crohn Disease 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for PURINETHOL

Trials by Country

Trials by Country for PURINETHOL
Location Trials
United States 152
Canada 10
Puerto Rico 4
Israel 4
Netherlands 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for PURINETHOL
Location Trials
Texas 12
North Carolina 6
Wisconsin 5
Washington 5
Tennessee 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for PURINETHOL

Clinical Trial Phase

Clinical Trial Phase for PURINETHOL
Clinical Trial Phase Trials
Phase 4 2
Phase 3 8
Phase 2 11
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for PURINETHOL
Clinical Trial Phase Trials
Completed 11
Not yet recruiting 7
Recruiting 6
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for PURINETHOL

Sponsor Name

Sponsor Name for PURINETHOL
Sponsor Trials
National Cancer Institute (NCI) 11
Children's Oncology Group 8
M.D. Anderson Cancer Center 6
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for PURINETHOL
Sponsor Trials
Other 22
Industry 12
NIH 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
Medtronic
Moodys
Johnson and Johnson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.